Compare Novartis AG (NVS) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Oracle Corporation — how do they compare? Novartis AG trades at $143.34 (market cap $268.57B), while Oracle Corporation trades at $140.54 (market cap $411.34B). The key difference: Oracle Corporation is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Oracle Corporation for 72 Days on average.
| NVS | ORCL | |
|---|---|---|
Market Cap | $268.57B | $411.34B |
Volume | 1,532,573 | 41,276,815 |
Sector | Health | Technology |
52-Week High | $168.62 | $313.00 |
52-Week Low | $121.80 | $114.99 |
Typical Hold Time | 82 Days | 72 Days |
Enterprise Value | $309.89B | $535.15B |
Dividend Yield | 3.31% | 1.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Oracle (ORCL) trades at $143.56, down 0.83% amid a bearish technical signal, though recent earnings consistently beat expectations with Q2 2026 EPS of $1.92 versus $1.74 expected. The company shows strong fundamentals with 2025 revenue of $57.40B and net income margin of 26.36%, while analyst consensus remains bullish with a $236.52 price target. News highlights AI cloud growth of 120% in Q1 2026 but also layoffs and market concerns over AI spending cycles.
The outlook is mixed: robust AI-driven revenue growth and high profitability support upside, but technical weakness and macroeconomic risks like Fed policy pose near-term headwinds. Investors face opportunity from AI demand against volatility from high debt and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
